SUBSCRIBE
SUBSCRIBE

Phase III

Drug Development
Helsinn and MEI Discontinue Phase III Trial of Pracinostat in AML
The decision was made after an interim futility analysis by an Independent Data Monitoring Committee determined the trial was unlikely to meet the primary endpoint of overall survival (OS) compared to the control group.
July 2, 2020
 · 
3 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: July 1
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 1, 2020.
June 30, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: June 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 29, 2020.
June 29, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Drug Development
Two Patient Deaths Halt Audentes’ Gene Therapy Trial
San Francisco-based Audentes Therapeutics reported two deaths in its gene therapy clinical trial. The therapy, AT132, is for X-linked myotubular myopathy.
June 29, 2020
 · 
3 min read
 · 
Mark Terry
Drug Development
Clinical Catch-Up: June 22-26
It was a busy week for clinical trial updates. Here’s a look.
June 26, 2020
 · 
7 min read
 · 
Mark Terry
Drug Development
Moderna Partners with Catalent to Deepen COVID-19 Manufacturing Capabilities
With Moderna on the precipice of launching its Phase III trial of 30,000 people for its COVID-19 vaccine, mRNA-1273, it is ramping up manufacturing capabilities.
June 26, 2020
 · 
3 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: June 26
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.
June 25, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
FDA Approves Phase III Study of Fulcrum’s Losmapimod in COVID-19
Shares of Fulcrum Therapeutics were up more than 14% in premarket trading after the company announced it will begin the Phase LOSVID III study to assess losmapimod as a potential treatment of COVID-19.
June 24, 2020
 · 
3 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: June 24
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
June 23, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Myovant’s Relugolix Combo Hits the Mark in Endometriosis, Heads to FDA for Prostate Cancer
Relugolix is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist.
June 23, 2020
 · 
3 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Press Releases
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
January 23, 2026
 · 
17 min read
Press Releases
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
January 23, 2026
 · 
7 min read
Press Releases
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
January 22, 2026
 · 
17 min read
Press Releases
IntraBio Announces Positive Pivotal Trial Results of Levacetylleucine for the Treatment of Ataxia-Telangiectasia
January 21, 2026
 · 
5 min read
Press Releases
LEO Pharma advances Anzupgo® (delgocitinib) cream to phase 3 trial in lichen sclerosus (LS)
January 21, 2026
 · 
7 min read
Press Releases
FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study
January 21, 2026
 · 
5 min read
Press Releases
Tanabe Pharma America Announces Positive Topline Results for Dersimelagon in Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)
January 21, 2026
 · 
5 min read
Press Releases
SpyGlass Pharma Announces First Patients Randomized in SGP-005 and SGP-006, Two Registrational Phase III Clinical Trials of Its Novel BIM-IOL System
January 20, 2026
 · 
5 min read
Press Releases
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
January 19, 2026
 · 
7 min read
Press Releases
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
January 19, 2026
 · 
13 min read
Press Releases
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
January 19, 2026
 · 
13 min read
Press Releases
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
January 19, 2026
 · 
9 min read
Press Releases
New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder
January 19, 2026
 · 
17 min read
Press Releases
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
January 16, 2026
 · 
6 min read
Press Releases
Almirall Announces “LumiNE”, a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema
January 16, 2026
 · 
7 min read
Press Releases
TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
January 15, 2026
 · 
34 min read
Press Releases
Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly’s Olumiant®
January 15, 2026
 · 
5 min read
Press Releases
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
January 14, 2026
 · 
13 min read
Press Releases
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
January 14, 2026
 · 
9 min read
Press Releases
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2
January 14, 2026
 · 
4 min read
Load More